SEARCH RESULTS

10 RESULTS

A. David Smith on Biogen/Eisai Halt Phase 3 Aducanumab Trials

COMMENT Several members have pointed out that the disappointing outcome of the aducanumab trial was not totally unexpected. As Kasper Kepp wrote, there are other hypotheses to account for the association of Aβ with AD. Nine years ago, I asked why we don't ...

Current Filters

  • TYPE: Comment x
  • Commentator: Smith, A. David x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE